New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
11:29 EDTRPRX, UTHR, GME, RHT, TIBXOptions with decreasing implied volatility: RPRX UTHR GME RHT TIBX
News For RPRX;UTHR;GME;RHT;TIBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 18, 2014
17:31 EDTRHTRed Hat raises FY15 EPS guidance by 1c to $1.53-$1.55, consensus $1.54
Subscribe for More Information
17:31 EDTRHTRed Hat sees Q3 EPS approximately 40c, consensus 41c
Sees Q3 revenue $449M-$452M, consensus $457.77M. Sees operating margin approximately 25%. Guidance provided during Q2 earnings conference call.
16:54 EDTTIBXTIBCO down over 4% following weaker than expected Q4 outlook
Subscribe for More Information
16:43 EDTTIBXTIBCO sees Q4 adjusted EPS 18c-24c, consensus 32c
Subscribe for More Information
16:06 EDTTIBXTIBCO reports Q3 non-GAAP EPS 14c, consensus 18c
Subscribe for More Information
16:05 EDTRHTRed Hat reports Q2 EPS 41c, consensus 38c
Reports Q2 revenue $445.9M, consensus $437.13M.
15:15 EDTTIBX, RHTNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Oracle (ORCL), consensus 64c; Red Hat (RHT), consensus 38c; TIBCO Software (TIBX), consensus 18c.
15:02 EDTTIBXTibco September 21 straddle priced for 7% move into Q3
Subscribe for More Information
15:00 EDTRHTRed Hat September 60 straddle priced for 6.7% move into Q2
14:21 EDTRHTRed Hat technical comments before earnings
Subscribe for More Information
13:38 EDTRPRXRepros needed unique Androxal label even before ADCOM panel, says Ladenburg
Ladenburg said that given the FDA advisory committee's 20 to 1 vote that it believes the FDA will likely revise testosterone replacement therapy labels to restrict their use in hypogonadal patients with clear etiology. However, Ladenburg added that Repros was always going to have to establish a unique label for Androxal and the firm believes that the company's ongoing and completed trials will provide sufficient data for filing and approval by the FDA in secondary hypogonadism. The firm maintains its Buy rating and $35 price target on Repros.
12:45 EDTRPRXOn The Fly: Midday Wrap
Subscribe for More Information
11:15 EDTRPRXRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
10:52 EDTRPRXOptions with increasing implied volatility
Options with increasing implied volatility: RPRX VALE NLY AGNC
10:09 EDTTIBXTibco Software volatility elevated into Q3 and outlook
Subscribe for More Information
08:02 EDTRHTRed Hat to acquire FeedHenry for EUR63.5M in cash
Red Hat announced that it has signed a definitive agreement to acquire FeedHenry, an enterprise mobile application platform provider. FeedHenry expands Red Hatís broad portfolio of application development, integration, and Platform-as-a-Service solutions, enabling Red Hat to support mobile application development in public and private environments. Red Hat has agreed to acquire FeedHenry, a privately held company, for approximately EUR 63.5M in cash, subject to certain adjustments at closing. The transaction is expected to close in 3Q15, subject to customary closing conditions.
07:19 EDTRPRXRepros Therapeutics sell-off overdone, says Brean Capital
Brean Capital said the selling in Repros Therapeutics is overdone after an FDA panel voted overwhelmingly in support for a more restrictive label that limits the use of TRT drugs to only patients with classic hypogonadism. The firm feels since Androxal has not been targeting age-related hypogonadism it does not deserve to be negatively impacted by yesterday's ruling. Brean Capital maintains its Buy rating on Repros Therapeutics and $41 price target on the shares.
07:00 EDTRPRXRepros Therapeutics price target lowered to $13 from $24 at Piper Jaffray
Subscribe for More Information
06:10 EDTRPRXFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
07:58 EDTRHTRed Hat October volatility elevated into Q2 and outlook
Red Hat September call option implied volatility is at 92, October is at 36, December is at 29; compared to its 26-week average of 30 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on September 18.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use